• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Consistent Efficacy With a Durable Safety Profile Through 5 Years and a Growing Body of Real-World Evidence


At the 2022 Fall Clinical Dermatology Conference in Las Vegas, Aaron S. Farberg, MD, shares data on the treatment of plaque psoriasis using tildrakizumab-asmn.

“Here is where you want to be: you don’t want to be in one of those other session rooms, showing the same old phase 3 data: this is where you will get new data and real world evidence on treatment for plaque psoriasis,” joked Aaron S. Farber, MD, medical director, Derm Texas and Dermatology Research Institute and assistant professor of Dermatology, Baylor Scott & White Health System Dermatology in Dallas, Texas. In this session on tildrakizumab-asmn (ILUMYA), sponsored by Sun Pharmaceuticals, Farberg delved into the efficacy and safety profiles for this injectable treatment for plaque psoriasis.

Tildrakizumab-asmn specifically targets IL-23, which is a critical cytokine in the immunopathogenesis of plaque psoriasis. Farberg shared clinical trial data from patients who had 2 injections of this treatment, showing more than half were clear or almost clear at the 12 week mark. By the time of the third shot, patients in the trial were 100% clear. “And, like a glass of fine wine, this treatment just gets better over time,” said Farberg. Patient response progressively improved through week 12, sustaining through 5 years.

In addition, real world evidence from 3 different studies showed durable improvement at multiple points using this medication, showing patients were 95% and 98% clearer at week 24 in 2 studies, and 91% clearer at year 1 in the third study.

When it comes to adverse events, one placebo group actually showed higher AEs (54%) than those treated with tildrakizumab-asmn. The most common AEs, pulled from phase 2 and 3 data sets (upper respiratory infection, injection-site reactions, and diarrhea) were 14%, 3%, and 2%, respectively.

Patients with comorbidities such as metabolic syndrome, who are at higher risk for psoriasis, were looked at as well. The improvement in these patients were almost identical to those without this disorder.

Tildrakizumab-asmn, 100 mg/mL, is a single-injection, prefilled syringe, administered, after initial injection dosages, every 4 months.


Farberg AS. Consistent efficacy with a durable safety profile through 5 years and a growing body of real-world evidence. 2022 Fall Clinical Dermatology Conference. October 21, 2022. Las Vegas, Nevada.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.